News & Updates

Clinical trials on first-line therapies for advanced or metastatic nonsmall cell lung cancer (NSCLC) from 2010 to 2020 have reported better survival and a steady improvement in quality of life (QoL) among patients, according to the results of a systematic review.

Use of behavioural interventions, specifically multicomponent and patient navigation interventions, helps increase the uptake of colonoscopy for colorectal cancer (CRC) screening, reveals a study.

Adding percent free prostate-specific antigen (PSA) to total PSA results in better prediction of clinically significant prostate cancer and fatal prostate cancer in men, reports a study.

In the first-line treatment of patients with advanced nonsmall cell lung cancer (NSCLC) harbouring EGFR mutation, the combination of osimertinib plus pemetrexed and platinum-based chemotherapy outperformed osimertinib alone in terms of extending progression-free survival (PFS), according to the interim results of the phase III FLAURA2 trial presented at WCLC 2023.

In children with cancer receiving chemotherapy, factors such as age and susceptibility to motion sickness are associated with the risk of acute chemotherapy-induced nausea (CIN), reports a study.

Cancer patients who are being treated with chemotherapy are susceptible to chemotherapy-induced nausea and vomiting (CINV), and they continue to experience these side effects despite being administered with antiemetics, a study has shown.